Venturi Wealth Management LLC Invests $264,000 in TransMedics Group, Inc. $TMDX

Venturi Wealth Management LLC bought a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,973 shares of the company’s stock, valued at approximately $264,000.

Several other large investors also recently made changes to their positions in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of TransMedics Group by 244.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company’s stock worth $209,448,000 after purchasing an additional 2,209,996 shares during the last quarter. Driehaus Capital Management LLC grew its holdings in shares of TransMedics Group by 2.4% during the first quarter. Driehaus Capital Management LLC now owns 778,754 shares of the company’s stock worth $52,395,000 after purchasing an additional 17,913 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of TransMedics Group by 20.6% during the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after purchasing an additional 86,721 shares during the last quarter. Emerald Advisers LLC grew its holdings in shares of TransMedics Group by 22.4% during the first quarter. Emerald Advisers LLC now owns 454,794 shares of the company’s stock worth $30,599,000 after purchasing an additional 83,083 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in shares of TransMedics Group by 2.1% during the first quarter. Northern Trust Corp now owns 361,963 shares of the company’s stock worth $24,353,000 after purchasing an additional 7,341 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

TMDX has been the topic of several research analyst reports. Morgan Stanley increased their target price on TransMedics Group from $115.00 to $123.00 and gave the stock an “equal weight” rating in a report on Friday, August 1st. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a report on Monday, August 25th. Zacks Research cut TransMedics Group from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Oppenheimer raised their price target on TransMedics Group from $130.00 to $150.00 and gave the company an “outperform” rating in a report on Tuesday, June 17th. Finally, Evercore ISI initiated coverage on TransMedics Group in a report on Tuesday, September 16th. They issued an “outperform” rating and a $155.00 price target on the stock. Six investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $125.40.

TransMedics Group Price Performance

Shares of TMDX opened at $107.29 on Friday. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $145.50. The stock has a market cap of $3.66 billion, a P/E ratio of 55.59 and a beta of 2.08. The stock’s 50-day moving average price is $117.21 and its two-hundred day moving average price is $111.82.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.44. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The firm had revenue of $157.37 million for the quarter, compared to analysts’ expectations of $146.64 million. During the same quarter last year, the business earned $0.35 earnings per share. The company’s revenue was up 37.7% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. On average, equities analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.